Neuronix reports successful Alzheimer helmet trial

The Israeli startup's treatment is based on cognitive exercises and brain stimulation using a magnetic helmet.

Neuronix Ltd., which has developed an Alzheimer's disease treatment based on cognitive exercises using a computer game with brain stimulation by a magnetic helmet, reports good results during a product trial.

30 patients had been treated with the helmet with a significant improvement noted after six weeks. After the series of treatments their condition was better than before the first treatment, although the condition of Alzheimer patients usually worsens during six weeks. Even after ten months, patient deterioration was slower than documented in Alzheimer's disease research literature. At the same time, the trials were not controlled that is, the improvement in patient condition was not compared to a control group. This makes it more difficult to neutralize placebo effects stemming from participation in a clinical trial and not necessarily from the treatment itself.

After ten months, the patients underwent another series of treatment, with a repeated improvement resembling the first round.

Medical Manager of Neuronix Clinics in Israel Prof. Martin Rabey says: "This trial added to previous trials carried out in Israel and in the US, showing the treatment's short-term effectiveness (several weeks) in improving the patients' condition without significant side effects. This trial is different because patients' condition was monitored for up to a year, enabling us to see their functioning stabilizing and then improving again after a treatment course."

RELATED ARTICLES

Neuronix received a permission to submit the system to the US Food and Drug Administration (FDA) expedited access pathway (EAP) clearance. So far, only 17 technologies were accepted to the EAP. Neuronix estimates that the application will be submitted to the FDA in the summer of 2016.

Neuronix, managed by Eyal Baror, attempted an IPO at the Tel Aviv Stock Exchange (TASE) in the past but, after proving unsuccessful, raised $5.5 million in a private placement, at a larger value than its IPO target.